Two intermediate-avidity cytotoxic T lymphocyte clones with a disparity between functional avidity and MHC tetramer staining

被引:51
作者
Derby, MA
Wang, J
Margulies, DT
Berzofsky, JA
机构
[1] NCI, Mol Immunogenet & Vaccine Res Sect, Metab Branch, NIH, Bethesda, MD 20892 USA
[2] NIAID, Mol Biol Sect, Immunol Lab, NIH, Bethesda, MD 20892 USA
关键词
antigen binding; FACS; TCR; vaccinia; mouse;
D O I
10.1093/intimm/13.6.817
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The efficacy of cytotoxic T lymphocytes (CTL) has been shown to be highly dependent upon their functional avidity (the sensitivity of their cellular response to MHC-peptide complexes), To examine this relationship, we employed target cell lysis as a quantitative measure and established a set of four CTL clones that exhibited a range of functional avidities spanning more than three orders of magnitude. Within this set, clones displayed a linear correlation between functional avidity and the TCR down-regulation that occurred in response to increasing antigen density. Staining intensity of MHC-peptide tetramer, however, correlated only with the very highest and very lowest avidity clones; the two intermediate-avidity clones showed an inverse relationship between tetramer staining and functional avidity. Compensation for differences in surface levels of TCR improved the correlation, but failed to fully account for this discrepancy. Comparison of TCR signals generated by stimulation of CTL with substrate-bound soluble MHC-peptide or antigen-presenting cells suggested that internal TCR signaling efficiency accounts for at least a portion of the observed functional avidity and suggests the need for caution in directly relating tetramer staining to avidity.
引用
收藏
页码:817 / 824
页数:8
相关论文
共 27 条
[1]   Supraoptimal peptide major histocompatibility complex causes a decrease in Bcl-2 levels and allows tumor necrosis factor α receptor II-mediated apoptosis of cytotoxic T lymphocytes [J].
Alexander-Miller, MA ;
Derby, MA ;
Sarin, A ;
Henkart, PA ;
Berzofsky, JA .
JOURNAL OF EXPERIMENTAL MEDICINE, 1998, 188 (08) :1391-1399
[2]   Selective expansion of high- or low-avidity cytotoxic T lymphocytes and efficacy for adoptive immunotherapy [J].
AlexanderMiller, MA ;
Leggatt, GR ;
Berzofsky, JA .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1996, 93 (09) :4102-4107
[3]   Phenotypic analysis of antigen-specific T lymphocytes [J].
Altman, JD ;
Moss, PAH ;
Goulder, PJR ;
Barouch, DH ;
McHeyzerWilliams, MG ;
Bell, JI ;
McMichael, AJ ;
Davis, MM .
SCIENCE, 1996, 274 (5284) :94-96
[4]   Detection of antigen-specific T cells with multivalent soluble class II MHC covalent peptide complexes [J].
Crawford, F ;
Kozono, H ;
White, J ;
Marrack, P ;
Kappler, J .
IMMUNITY, 1998, 8 (06) :675-682
[5]   Critical role for CD8 in T cell receptor binding and activation by peptide/major or histocompatibility complex multimers [J].
Daniels, MA ;
Jameson, SC .
JOURNAL OF EXPERIMENTAL MEDICINE, 2000, 191 (02) :335-345
[6]   Accessing complexity: The dynamics of virus-specific T cell responses [J].
Doherty, PC ;
Christensen, JP .
ANNUAL REVIEW OF IMMUNOLOGY, 2000, 18 :561-592
[7]   REMOVAL OF CRYPTIC POXVIRUS TRANSCRIPTION TERMINATION SIGNALS FROM THE HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 ENVELOPE GENE ENHANCES EXPRESSION AND IMMUNOGENICITY OF A RECOMBINANT VACCINIA VIRUS [J].
EARL, PL ;
HUGIN, AW ;
MOSS, B .
JOURNAL OF VIROLOGY, 1990, 64 (05) :2448-2451
[8]   The Immunological Synapse: A Molecular Machine Controlling T Cell Activation [J].
Grakoui, Arash ;
Bromley, Shannon K. ;
Sumen, Cenk ;
Davis, Mark M. ;
Shaw, Andrey S. ;
Allen, Paul M. ;
Dustin, Michael L. .
JOURNAL OF IMMUNOLOGY, 2015, 194 (09) :221-227
[9]   Direct visualization of antigen-specific T cells:: HTLV-1 Tax11-19-specific CD8+ T cells are activated in peripheral blood and accumulate in cerebrospinal fluid from HAM/TSP patients [J].
Greten, TF ;
Slansky, JE ;
Kubota, R ;
Soldan, SS ;
Jaffee, EM ;
Leist, TP ;
Pardoll, DM ;
Jacobson, S ;
Schneck, JP .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1998, 95 (13) :7568-7573
[10]  
Itoh Y, 1999, J IMMUNOL, V162, P2073